Combination chemotherapy with cyclophosphamide, adriamycin, and vincristine in malignant thymoma and myasthenia gravis.

Malignant thymoma (MT) is a rare tumor that is often associated with myasthenia gravis (MG). This tumor is considered resistant to chemotherapy. We had the opportunity to treat five patients with MT with cyclophosphamide 800 mg/m2, Adriamycin 50 mg/m2, and vincristine 1.4 mg/m2 (CAV) in cycles of 21 days. Two patients with MG that was resistant to antimyasthenic drugs immediately responded to this combination. One patient with only MT had a complete response, and two patients with only MT had a partial response. Two out of the five patients are still alive and free of disease. Two patients died of disease, and one died from a neutropenia-induced respiratory tract infection. It is concluded that this combination chemotherapy is active in MT and MG and deserves additional trials.
AuthorsP A Kosmidis, E Iliopoulos, S Pentea
JournalCancer (Cancer) Vol. 61 Issue 9 Pg. 1736-40 (May 1 1988) ISSN: 0008-543X [Print] UNITED STATES
PMID3355974 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis (drug therapy, etiology)
  • Thymoma (complications, drug therapy, therapy)
  • Thymus Neoplasms (complications, drug therapy, therapy)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: